STADA Arzneimittel — Investor Presentation (April 2024)
25 slides from STADA Arzneimittel's investor presentation, Apr 22, 2024
Slide 1: Introduction to STADA
CONFIDENTIAL Introduction to STADA A leading provider of healthcare products in Europe and beyond April 2024
Slide 2: Important Notice
CONFIDENTIAL Important Notice This presentation has been prepared by Nidda German Topco GmbH (the “Company”) and its subsidiaries, including STADA Arzneimittel Aktiengesellschaft (collectively, the “Group”), and shall mean and include the following slides, any oral presentation of the slides by the
Slide 3: Important Notice
CONFIDENTIAL Important Notice The information contained in this Presentation is not to be viewed from nor for publication or distribution in nor taken or transmitted into the United States of America ("United States"), Australia, Canada or Japan and does not constitute an offer of securities for sal
Slide 4: STADA has a clear purpose, vision and values
CONFIDENTIAL STADA’s has a clear purpose, vision and values Purpose Vision Values Caring for To Be The Partner of Choice Integrity People’s Health in Consumer Healthcare, Entrepreneurship as a Trusted Partner Generics and Specialty while Agility Continuously Outgrowing the One STADA Industry in Term
Slide 5: STADA's Strategic Frame
CONFIDENTIAL STADA’s Strategic Frame Purpose “Caring for people’s health as a trusted partner” “To be the partner of choice in Consumer Health, Generics and Vision Specialty continuously outgrowing the industry in terms of sales and profit” Consumer Health, Total Europe incl. Eurasia, Generics and S
Slide 6: STADA has over 125 years of heritage, rooted in the pharmacy channel
CONFIDENTIAL STADA has over 125 years of heritage, rooted in the pharmacy channel and with public market experience; take-private has transformed and positioned it for future growth Net Sales Key highlights since take-private €3.7bn(1) 4,000. 0 Climbed to top 4 position in Consumer Healthcare in Eur
Slide 7: STADA today: A pan-European leader in Consumer Healthcare, Generics and Specialty
CONFIDENTIAL STADA today: A pan-European leader in Consumer Healthcare, Generics and Specialty medicines with a track record of outperforming attractive markets Key stats Net Sales €3.7bn FY23E(1) +13% vs. PY Top 4 ~11.5k >200 CHC(2) and Gx(3) employees, incl. ~3.2k(5) Well positioned brands player
Slide 8: STADA has significant size and scale across its three segments
CONFIDENTIAL STADA has significant size and scale across its three segments % of FY23E(1) 40% 40% 20% net sales Consumer Generics Specialty Healthcare Non-prescription Off-patent prescription drugs sold under Includes Branded / Specialty Generics Overview International Non-proprietary Name (INN) (fo
Slide 9: STADA offers a compelling investment case in European Healthcare
CONFIDENTIAL STADA offers a compelling investment case in European Healthcare Large, growing and resilient addressable markets of ~$100bn 1 Consumer Healthcare, Generics & Specialty European market(1) growing at high-single digits(2) A leading integrated platform which is outperforming competition #
Slide 10: STADA's addressable markets are attractive, large, growing and resilient
CONFIDENTIAL 1. LARGE, GROWING AND RESILIENT ADDRESSABLE MARKETS 1 STADA's addressable markets across Consumer Healthcare, Generics and Specialty are attractive, large, growing and highly resilient THE CHC MARKET IS SIZEABLE & SET TO …WHILE THE MOMENTUM IN THE GX MARKET …DRIVEN BY THE LAUNCH OF EXPE
Slide 11: STADA is a market leader across its segments and is outgrowing markets
CONFIDENTIAL 2. A LEADING INTEGRATED PLATFORM WHICH IS OUTPERFORMING COMPETITION AND GROWING FASTER THAN RELEVANT MARKETS DRIVEN BY CULTURE 2 STADA is a market leader across its segments, and is outgrowing the markets in which it operates Consumer Healthcare 40% Generics 40% Specialty 20% #1 in Germ
Slide 12: STADA's integrated platform is uniquely positioned compared to its peer group
2. A LEADING INTEGRATED PLATFORM WHICH IS OUTPERFORMING COMPETITION AND GROWING FASTER THAN RELEVANT MARKETS DRIVEN BY CULTURE CONFIDENTIAL 2 STADA's integrated platform is uniquely positioned compared to its peer group Consumer Healthcare Generics Specialty Recordati is the closest peer to STADA; y
Slide 13: STADA's outperformance is supported by highly symbiotic segments
CONFIDENTIAL 2. A LEADING INTEGRATED PLATFORM WHICH IS OUTPERFORMING COMPETITION AND GROWING FASTER THAN RELEVANT MARKETS DRIVEN BY CULTURE 2 STADA's resilient outperformance of the market is supported by its highly symbiotic segments, which drive meaningful synergies along the value-chain SYNERGY A
Slide 14: STADA's growth culture is the key differentiator
2. A LEADING INTEGRATED PLATFORM WHICH IS OUTPERFORMING COMPETITION AND GROWING FASTER THAN RELEVANT MARKETS DRIVEN BY CULTURE CONFIDENTIAL 2 STADA’s growth culture is the key differentiator and a driver behind its performance Constant improvement in employee engagement survey participation rates Un
Slide 15: TechOps is an integrated organization with a balanced network
CONFIDENTIAL 3. HIGHLY INTEGRATED TECHOPS ORGANIZATION ENABLES COMPETITIVE COST ACROSS SEGMENTS AND PRODUCTS 3 TechOps is an integrated organization with a balanced internal and external network providing reliable, cost-competitive, and compliant supply across segments TechOps key figures(1) COGS br
Slide 16: TechOps enables efficient cost control on external supply and internal manufacturing
CONFIDENTIAL 3. HIGHLY INTEGRATED TECHOPS ORGANIZATION ENABLES COMPETITIVE COST ACROSS SEGMENTS AND PRODUCTS 3 STADA's TechOps enables highly efficient cost control on both external supply operations and internal manufacturing footprint STADA’s approach to external supply Highly efficient and cost c
Slide 17: Strong commercial infrastructure across Europe and Emerging Markets
4. FULLY INVESTED AND HIGHLY SCALABLE PLATFORM WITH STRONG DEVELOPMENT AND REGULATORY CAPABILITIES CONFIDENTIAL 4 STADA has strong commercial infrastructure across all of Europe and several Emerging Markets – and a global reach in terms of BD&L – and Procurement Full commercial coverage of Europe an
Slide 18: Strong development capabilities make STADA a leading innovator
4. FULLY INVESTED AND HIGHLY SCALABLE PLATFORM WITH STRONG DEVELOPMENT AND REGULATORY CAPABILITIES CONFIDENTIAL 4 Strong development capabilities make STADA a leading innovator Product Development Geographical Footprint and Set up Unique Product Development platform Site Country Product Development
Slide 19: Track record of creating value through pipeline development
4. FULLY INVESTED AND HIGHLY SCALABLE PLATFORM WITH STRONG DEVELOPMENT AND REGULATORY CAPABILITIES CONFIDENTIAL 4 STADA has a track record of successfully creating value through pipeline development Strong track record with launches(2) contributing on average 4% of YoY growth since 2020 €m ~5% % of
Slide 20: STADA is the BD&L partner of choice for all 3 segments
CONFIDENTIAL 5. PARTNER OF CHOICE FOR M&A AND BD&L ACTIVITY WITH PROVEN INTEGRATION AND ACCELERATION CAPABILITIES 5 Strong global footprint and track-record make STADA the BD&L partner of choice for all 3 segments, allowing in-licensing at competitive terms Licensing Deals Development Network Highli
Slide 21: STADA is Pharma's partner of choice for M&A
CONFIDENTIAL 5. PARTNER OF CHOICE FOR M&A AND BD&L ACTIVITY WITH PROVEN INTEGRATION AND ACCELERATION CAPABILITIES 5 STADA has demonstrated itself to be Pharma's partner of choice for M&A with strong integration capabilities M&A > 20 M&A deals €1.3bn investment(4)(5) 200+ brands 3,000+ SKUs stats: No
Slide 22: Highly-skilled management team with a track record of execution
6. HIGHLY-SKILLED MANAGEMENT TEAM CONFIDENTIAL 6 Highly-skilled management team with a track record of successful execution Sector expertise Name & position Prior experience CHC Gx Sx Peter Goldschmidt Chief Executive Officer Boris Döbler Chief Financial Officer Simone Berger Chief People Officer Mi
Slide 23: An ESG leader among top 2% of pharma companies
CONFIDENTIAL 7. ESG LEADERSHIP AND LONG-TERM SUSTAINABILITY 7 An ESG leader among top 2% of pharma companies with a well-developed strategy (1) and ambitious goals Top 2% of pharma ESG governance 2nd externally verified ESG strategy aligned companies with the structure with firm Sustainability Repor
Slide 24: Attractive financial profile
CONFIDENTIAL 8. ATTRACTIVE FINANCIAL PROFILE 8 Above-market organic topline-growth, accretive EBITDA-growth at healthy margins and strong cash flow generation Reported Net Sales Adjusted EBITDA(2) Strong Cash flow(4) generation Net Sales growth by segment Adjusted EBITDA(2) margin by segment(3) >80%
Slide 25: Building the foundation for long-term profitable and sustainable growth
CONFIDENTIAL Building the foundation for long-term profitable and sustainable growth Track record and platform to Further shift to higher margin continue to outperform attractive consumer and specialty markets which are growing at businesses >5% p.a. Continued investment in state- Selectively expand
STADA Arzneimittel — Investor Presentation (April 2024) on 6ix